EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieOpen Access · CC BY-NC 4.0

Efficacy and Safety of Alogliptin-Pioglitazone Combination for Type 2 Diabetes Mellitus Poorly Controlled with Metformin: A Multicenter, Double-Blind Randomized Trial

Ji-Yeon Park, Joonyub Lee, Yoon-Hee Choi, Kyung Wan Min, Kyung Ah Han, Kyu Jeung Ahn, Soo Lim, Young-Hyun Kim, Chul Woo Ahn, Kyung Mook Choi, Kun-Ho Yoon

Diabetes & Metabolism Journal · 2024

DOI: 10.4093/dmj.2023.0259 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Diabetes & Metabolism Journal, 2024. Verfasst von Ji-Yeon Park und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology and Metabolism, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of…. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Glycated Hemoglobin, Hypoglycemic Agents, Metformin. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Guidelines for switching to triple combination therapy directly after monotherapy failure are limited. This study investigated the efficacy, long-term sustainability, and safety of either mono or dual add-on therapy using alogliptin and pioglitazone for patients with type 2 diabetes mellitus (T2DM) who did not achieve their target glycemic range with metformin monotherapy.

Methods

The Practical Evidence of Antidiabetic Combination Therapy in Korea (PEAK) was a multicenter, placebo-controlled, double-blind, randomized trial. A total of 214 participants were randomized to receive alogliptin+pioglitazone (Alo+Pio group, n=70), alogliptin (Alo group, n=75), or pioglitazone (Pio group, n=69). The primary outcome was the difference in glycosylated hemoglobin (HbA1c) levels between the three groups at baseline to 24 weeks. For durability, the achievement of HbA1c levels

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Glycated HemoglobinHypoglycemic AgentsMetforminPioglitazonePiperidinesAdultAgedFemaleHumansMaleMiddle AgedBlood GlucoseDouble-Blind MethodDrug Therapy, CombinationRepublic of KoreaTreatment OutcomeUracil

Stichwörter der Autor:innen

AlogliptinDiabetes mellitus, type 2Glycated hemoglobinHypoglycemic agentsMetforminPioglitazone

Substanzen

alogliptinBlood GlucoseGlycated Hemoglobinhemoglobin A1c protein, humanHypoglycemic AgentsMetforminPioglitazonePiperidinesUracil

Autor:innen und Institutionen

  • Division of Endocrinology and Metabolism, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
  • MedicalExcellence Inc., Seoul, Korea.
  • Division of Endocrinology and Metabolism, Department of Internal Medicine, Eulji General Hospital, Eulji University School of Medicine, Seoul, Korea.
  • Division of Endocrinology and Metabolism, Kyung Hee University Hospital at Gangdong, College of Medicine, Kyung Hee University, Seoul, Korea.
  • Division of Endocrinology and Metabolism, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea.
  • Division of Endocrinology and Metabolism, Bundang Jesaeng Hospital, Seongnam, Korea.

Zitieren

APA

Park, J. Y., Lee, J., Choi, Y. H., Min, K. W., Han, K. A., Ahn, K. J., Lim, S., Kim, Y. H., Ahn, C. W., Choi, K. M., & Yoon, K. H. (2024). Efficacy and Safety of Alogliptin-Pioglitazone Combination for Type 2 Diabetes Mellitus Poorly Controlled with Metformin: A Multicenter, Double-Blind Randomized Trial. Diabetes & Metabolism Journal. https://doi.org/10.4093/dmj.2023.0259

Vancouver

Park JY, Lee J, Choi YH, Min KW, Han KA, Ahn KJ, et al. Efficacy and Safety of Alogliptin-Pioglitazone Combination for Type 2 Diabetes Mellitus Poorly Controlled with Metformin: A Multicenter, Double-Blind Randomized Trial. Diabetes & Metabolism Journal. 2024. doi:10.4093/dmj.2023.0259

BibTeX
@article{Park2024,
  author = {Park, Ji-Yeon and Lee, Joonyub and Choi, Yoon-Hee and Min, Kyung Wan and Han, Kyung Ah and Ahn, Kyu Jeung and Lim, Soo and Kim, Young-Hyun and Ahn, Chul Woo and Choi, Kyung Mook and Yoon, Kun-Ho},
  title = {Efficacy and Safety of Alogliptin-Pioglitazone Combination for Type 2 Diabetes Mellitus Poorly Controlled with Metformin: A Multicenter, Double-Blind Randomized Trial},
  journal = {Diabetes & Metabolism Journal},
  year = {2024},
  doi = {10.4093/dmj.2023.0259}
}
Kostenlos starten →